Harmful neutrophil subsets in patients with ischemic stroke
Association with disease severity
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective To better understand the functional state of circulating neutrophils in patients with ischemic stroke (IS) for planning future clinical trials.
Methods We analyzed by flow cytometry activation state of circulating neutrophils and the distribution of neutrophil peripheral subsets in 41 patients with acute IS less than 6 hours before admission and compared them with 22 age-matched healthy controls.
Results Our results demonstrated continuous basal hyperactivation of circulating neutrophils during acute IS, characterized by lower l-selectin expression and higher CD11b expression at the cell surface, increased ROS production by neutrophils, and greater circulating levels of neutrophil elastase. Neutrophil hyperactivation was associated with deregulation of the equilibrium between apoptotic and necrotic. Patients also had higher percentages than controls of the overactive senescent (CXCR4bright/CD62Ldim) neutrophil subset and increased percentage of neutrophils with a reverse transendothelial migration (CD54highCXCR1low) phenotype. Importantly, neutrophil alterations were associated with the clinical severity of the stroke, evaluated by its NIH Stroke Scale score.
Conclusion Altogether, our results indicate that during acute IS, the inflammatory properties of circulating neutrophils rise, associated with the expansion of harmful neutrophil subsets. These changes in neutrophil homeostasis, associated with disease severity, may play an instrumental role by contributing to systemic inflammation and to the blood-brain barrier breakdown. Our findings highlight new potential therapeutic approaches of stroke by rebalancing the ratio of senescent to immunosuppressive neutrophils or decreasing reverse neutrophil transmigration or both.
Glossary
- AAD=
- amino-actinomycin D;
- ANOVA=
- analysis of variance;
- APC=
- allophycocyanine;
- BBB=
- blood-brain barrier;
- DAMP=
- danger-associated molecular pattern;
- fMLP=
- N-formylmethionyl-leucyl-phenylalanine;
- HC=
- healthy control;
- HE=
- hydroethidine;
- HMGB=
- high-mobility group box;
- IS=
- ischemic stroke;
- LPS=
- lipopolysaccharide;
- MMP=
- matrix metalloproteinase;
- MPO=
- myeloperoxidase;
- NET=
- neutrophil extracellular trap;
- NIHSS=
- NIH Stroke Scale;
- NLR=
- Nod-like receptor;
- PBS=
- phosphate buffered saline;
- PMN=
- polymorphonuclear neutrophil;
- ROS=
- reactive oxygen species;
- rTEM=
- reverse transendothelial migration;
- sJAM-C=
- soluble JAM-C;
- TNF=
- tumor necrosis factor;
- TLR=
- Toll-like receptor
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information are provided at the end of the article.
The Article Processing Charge was funded by the authors.
Editorial, page e570
- Received December 19, 2018.
- Accepted in final form March 12, 2019.
- Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSSShahram Majidi, Marie Luby, John K. Lynch et al.Neurology, September 13, 2019 -
Null Hypothesis
Natalizumab in acute ischemic stroke (ACTION II)A randomized, placebo-controlled trialMitchell S.V. Elkind, Roland Veltkamp, Joan Montaner et al.Neurology, June 26, 2020 -
Research
Frequency of early rapid improvement in stroke severity during interfacility transferKori S. Zachrison, Thabele M. Leslie-Mazwi, Gregoire Boulouis et al.Neurology: Clinical Practice, May 08, 2019 -
Articles
Baseline NIH Stroke Scale Score predicting outcome in anterior and posterior circulation strokesS. Sato, K. Toyoda, T. Uehara et al.Neurology, April 23, 2008